Incivek treatment still effective when course is half as long in treatment of Hepatitis C genotype 1

A Phase III study (ADVANCE) of Incivek (telaprevir) tablets in patients with genotype 1 chronic Hepatitis C published in The New England Journal of Medicine (NEJM) reveals that a 24-week treatment course that adds Incivek to peginterferon alfa and ribavirin is just as effective as a 48-week regimen for many patients. Shortening the duration of treatment reduces a patient's exposure to side effects including rash and anemia.see Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection September 15, 2011Sherman K.E., Flamm S.L., Afdhal N.H., et al.N Engl J Med 2011; 365:1014 - 1024.